Get the Stockscreener App
1.23
1.60%
-0.02
After Hours:
1.17
-0.06
-4.88%
Anebulo Pharmaceuticals Inc Stock (ANEB) Latest News
Anebulo Pharmaceuticals enters lock-up agreement, faces Nasdaq compliance issue By Investing.com - Investing.com South Africa
Anebulo Pharmaceuticals enters lock-up agreement, faces Nasdaq compliance issue - Investing.com
Anebulo Pharmaceuticals files to sell 15.15M shares of common stock for holders - MSN
Anebulo Pharmaceuticals Reports Fiscal Q2 2025 Results - TipRanks
Anebulo Pharmaceuticals Inc Files Prospectus Related To Resale Of 15.2 Million Shares Of Common Stock By Selling Stockholders- SEC Filing - Marketscreener.com
Anebulo Pharmaceuticals Inc. (ANEB) reports earnings - Quartz
Anebulo Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Anebulo Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Anebulo's Cannabis Overdose Treatment Gets FDA Priority Signal as Company Raises $15M - StockTitan
Head to Head Contrast: ProQR Therapeutics (NASDAQ:PRQR) versus Anebulo Pharmaceuticals (NASDAQ:ANEB) - Defense World
Anebulo Pharmaceuticals sets annual meeting for April 4, 2025 By Investing.com - Investing.com Nigeria
Anebulo Pharmaceuticals sets annual meeting for April 4, 2025 - MSN
Anebulo Pharmaceuticals Leads This Trio Of US Penny Stocks - Yahoo Finance
Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Increases By 2,174.1% - Defense World
Short Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Expands By 2,174.1% - Defense World
3 US Penny Stocks With Market Caps Under $800M - Yahoo Finance
Anebulo Pharmaceuticals sees $9.99m stock acquisition by 22NW fund - Investing.com Australia
Anebulo Pharmaceuticals collaborates with FDA to advance selonabant - Yahoo Finance
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise - BioSpace
Anebulo Pharmaceuticals secures $15 million capital raise - Investing.com
Anebulo Reports Breakthrough Clinical Data for Cannabis Toxicity Treatment, Secures $15M Funding - StockTitan
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Price Down 9.8% – Should You Sell? - Defense World
Anebulo Pharmaceuticals stock hits 52-week low at $1.23 - Investing.com India
Anebulo Pharmaceuticals stock hits 52-week low at $1.23 By Investing.com - Investing.com South Africa
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
Anebulo Pharmaceuticals stock hits 52-week low at $1.25 By Investing.com - Investing.com Australia
Anebulo Pharmaceuticals stock hits 52-week low at $1.25 - Investing.com India
Anebulo Pharmaceuticals Advances Cannabis Toxicity Solutions - MSN
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates - Defense World
Anebulo Pharma Secures $1.9M NIDA Grant for Cannabis Toxicity Treatment Development | ANEB Stock News - StockTitan
Anebulo Pharmaceuticals stock hits 52-week low at $1.72 - Investing.com
Anebulo Pharmaceuticals stock hits 52-week low at $1.72 By Investing.com - Investing.com UK
Exxaro Resources (OTCMKTS:EXXAY) Share Price Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Lexeo Therapeutics’ (LXEO) “Buy” Rating Reiterated at Chardan Capital - Defense World
Short Interest in Janone Inc. (NASDAQ:ALTS) Expands By 10.2% - Defense World
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.21% - MSN
Anebulo Pharmaceuticals Updates Corporate Presentation - TipRanks
Anebulo To Report Acute Cannabinoid Intoxication Trial Data In June - RTTNews
Benchmark maintains Speculative Buy on Anebulo stock By Investing.com - Investing.com Canada
Anebulo Pharmaceuticals (NASDAQ:ANEB) Earns "Speculative Buy" Rating from Benchmark - MarketBeat
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 27.7% in September - Defense World
Anebulo Pharmaceuticals reports Q4 EPS (5c) vs. (10c) last year - TipRanks
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended June 30, 2024 - Marketscreener.com
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates - Business Wire
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):